Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share,...| MENAFN.COM

Wednesday, 29 June 2022 01:56 GMT

Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share, Development, Key Opportunity, Application And Forecast 2022 - 2031

(MENAFN- America News Hour)

Kenneth Research, in its repository of market research reports, have recently added a report on Alpha-1 Antitrypsin Deficiency Treatment Market which emphasizes on the latest trends, key opportunities, drivers, and the challenges associated with the growth of the market during the forecast period, i.e., 2022 – 2031. The Alpha-1 Antitrypsin Deficiency Treatment Market is anticipated to grow primarily on account of the growing trade of ICT goods and services worldwide. According to the statistics by the World Bank, the exports of ICT goods globally increased from 11.164% of total goods exports in 2017 to 11.53% of total goods exports in 2019.

U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Alpha-1 Antitrypsin Deficiency Treatment Market products.

Download Sample of This Strategic Report- 

The Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market.Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions, expand their product portfolios, and improve their brand images.

For instance, on 3rd September 2019, Kamada Pharmaceuticals signed an agreement with Takeda Pharmaceutical Ltd for supply and distribution of Glassia, which is an alpha-1 proteinase inhibitor used for the treatment of alpha-1 antitrypsin deficiency.High unmet medical needs in developing economies are directly providing lucrative opportunities for the market growth.

Market Influencers

The rising number of product approvals. For instance, in September 2017, Grifols S.A. received a biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C.

Market Drivers

Increasing prevalence of alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency or AATD is a genetic disease that may cause severe lung or liver disfunction. The prevalence of alpha-1 antitrypsin deficiency is increasing, which is resulting in market growth. 1 in 1500 to 3500 Europeans are affected by AATD. Since the prevalence of AATD is increasing, the demand for treatment of AATD is also increasing, which is resulting in the positive growth of the alpha-1 antitrypsin deficiency treatment market.Growing product pipeline for alpha-1 antitrypsin deficiency treatment drugs

By Drugs

Alpha-1 Proteinase Inhibitor: This drug type is expected to hold the largest market share. In April 2019, CSL Behring received FDA approval for Zemaira, which is alpha-1 proteinase inhibitor. So, the rising number of product approvals is expected to drive the market growth.

Bronchodilators: Used for prevention from upper respiratory tract infections.Steroids: Consists of corticosteroids used for the treatment of COPD associated with AATD.Others: Consists of oxygen therapy, antibiotics, and other drugs used for the treatment of complications associated with AATD, such as jaundiced skin, breathing problems, etc.

By Route of Administration

Oral: This route of administration is expected to hold the largest market share due to its high usage.Intravenous: This drug type is expected to grow at the fastest rate owing to the ease of administration.Inhalation: This route of administration is mainly used for administration of corticosteroids and drugs for the treatment of breathing disorders associated with AATD.

Download Free Sample Reports Here – 

Others: Consists of subcutaneous and intramuscular routes of administration.

By Distribution Channel

Hospital Pharmacy: The segment holds the largest market size as the treatment is mostly carried out in hospitals.Retail Pharmacy: They provide prescriptions that are intended to be used at home.Online Stores: Fastest growing segment owing to the increasing number of online pharmacy stores.

By Region

Americas: The largest regional market. The high patient population suffering from alpha-1 antitrypsin deficiency is expected to drive the market growth. Approximately 1 in 2,500 Americans suffer from the disease. This serves to drive the growth of the alpha-1 antitrypsin deficiency treatment market in the region.Europe: Europe has some of the best healthcare services in the world. Increasing prevalence and the developed healthcare industry are driving the market growth.

Asia-Pacific: The fastest-growing regional market for alpha-1 antitrypsin deficiency treatment, Asia-Pacific has the world's largest population and fast-developing healthcare industry which is anticipated to drive the market growth.Middle East & Africa: The market growth is attributed to the developing healthcare industry in regions such as Saudi Arabia, Oman, and Qatar.

Key Players

Kamada Pharmaceuticals (Israel): Offers Glassia, an alpha-1 antitrypsin deficiency treatment drug. It also has inhalation AATD drug in Phase 2 clinical trials in the US and phase 3 clinical trials in Europe.CSL Behring LLC (US): Leading provider of plasma-derived and recombinant therapeutic products for rare diseases such as AATD. Hosted the symposium about AATD treatment in Paris.

Grifols, S.A. (Spain): Offers the Grifols Prolastin -C Liquid (alpha-1 proteinase inhibitor) for the treatment of AATD since 2017.Takeda Pharmaceutical Company Limited (Japan): Manufactures drugs for emphysema which is a main form of AATD.GlaxoSmithKline plc (UK): The company offers bronchodilators for the treatment of AATD.Boehringer Ingelheim GmbH (Germany): Manufacturer and distributor for bronchodilators.

AstraZeneca (UK): Offers bronchodilators such as the Bevespi Aerosphere inhalation aerosol for treatment of COPD associated with AATD.

Vectura Group plc (UK): Offers Ultibro Breezhaler dual bronchodilator.

Pfizer Inc. (US): Offers the Spiriva Handihaler bronchodilator for the treatment of COPD associated with AATD.

Mylan Inc. (US): Received FDA approval in November 2018 for YUPELRI, a long-acting muscarinic antagonist nebulized bronchodilator.

Request For Full Report- 

About Us
Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.

Contact Us
Name: Kenneth research
Phone: +1 313 462 0609

Mason Mount

Mason Mount is is an energetic and versatile freelance writer for 5 years, he pens down any type of article and web content. He is a Cambridge University Business English Certificate (Europe Level) holder. He is analytical, enthusiastic, and ingenious, with the essence to work variously, strives to emerge as a lucrative individual who has a grasp on market. Congenial Interpersonal skills and the competence to grab every single trivia with foolproof analysis is something he primarily posses.


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.